 Pulmonary tolerance prophylactic aerosolized pentamidine human immunodeficiency virus-infected patients effects primary secondary long-term prophylaxis Pneumocystis carinii pneumonia aerosolized pentamidine pulmonary function HIV+ patients patients none drug addicts pulmonary Kaposi sarcoma Fifty patients AP secondary prophylaxis monthly twice-monthly patients history PCP control subjects Twenty-three patients AP primary prophylaxis monthly twice-monthly Pulmonary function tests spirometry lung transfer capacity carbon monoxide Tlco alveolar-arterial oxygen gradient A-a ie month diagnosis PCP beginning AP prophylaxis three-month intervals differences results spirometry A-a patients secondary prophylaxis significant increase paired Student t-test Tlco group monthly administrations untreated control group significant difference Tlco patients monthly administrations period patients AP twice-monthly significant difference Tlco primary prophylaxis groups results pulmonary tolerance AP pulmonary function tests good